A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease.

ABSTRACT:

Background

Remdesivir is not currently approved for patients with eGFR <30 ml/min per 1.73 m². We aimed to determine the safety of remdesivir in patients with kidney failure.

Methods

This study was a retrospective cohort study of patients with COVID-19 hospitalized between May 2020 and January 2021 with eGFR <30 ml/min per 1.73 m² who received remdesivir and historical controls with COVID-19 hospitalized between March 1, 2020 and April 30, 2020 prior to the emergency use authorization of remdesivir within a large health care system. Patients were 1:1 matched by propensity scores accounting for factors associated with treatment assignment. Adverse events and hospital outcomes were recorded by manual chart review.

Results

The overall cohort include

SUBMITTER: Seethapathy R 

PROVIDER: S-EPMC8967642 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature